- Home
- NJR vs BLCO Comparison
NJR vs BLCO Comparison
Compare NJR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NJR
- BLCO
- Stock Information
- Founded
- NJR 1922
- BLCO 1853
- Country
- NJR United States
- BLCO Canada
- Employees
- NJR N/A
- BLCO N/A
- Industry
- NJR Oil/Gas Transmission
- BLCO Ophthalmic Goods
- Sector
- NJR Utilities
- BLCO Health Care
- Exchange
- NJR Nasdaq
- BLCO Nasdaq
- Market Cap
- NJR 4.6B
- BLCO 4.9B
- IPO Year
- NJR N/A
- BLCO 2022
- Fundamental
- Price
- NJR $45.76
- BLCO $13.51
- Analyst Decision
- NJR Hold
- BLCO Hold
- Analyst Count
- NJR 6
- BLCO 11
- Target Price
- NJR $51.33
- BLCO $15.80
- AVG Volume (30 Days)
- NJR 587.2K
- BLCO 959.5K
- Earning Date
- NJR 08-04-2025
- BLCO 07-30-2025
- Dividend Yield
- NJR 3.93%
- BLCO N/A
- EPS Growth
- NJR 63.33
- BLCO N/A
- EPS
- NJR 4.14
- BLCO N/A
- Revenue
- NJR $2,072,804,000.00
- BLCO $4,891,000,000.00
- Revenue This Year
- NJR $9.38
- BLCO $7.10
- Revenue Next Year
- NJR $3.00
- BLCO $5.50
- P/E Ratio
- NJR $11.06
- BLCO N/A
- Revenue Growth
- NJR 20.48
- BLCO 8.81
- 52 Week Low
- NJR $42.33
- BLCO $10.45
- 52 Week High
- NJR $51.95
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- NJR 50.16
- BLCO 47.98
- Support Level
- NJR $45.44
- BLCO $13.09
- Resistance Level
- NJR $46.19
- BLCO $15.13
- Average True Range (ATR)
- NJR 0.66
- BLCO 0.53
- MACD
- NJR -0.03
- BLCO -0.13
- Stochastic Oscillator
- NJR 28.24
- BLCO 20.59
About NJR NewJersey Resources Corporation
New Jersey Resources is an energy services holding company with regulated and nonregulated operations. Its regulated utility, New Jersey Natural Gas, delivers natural gas to nearly 600,000 customers in the state. NJR's nonregulated businesses include investments in commercial solar projects and several large midstream natural gas projects.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.